Clinical Trial Update: Prediction of Significant Hepatic Fibrosis in HCV Carriers With PNALT by SAPI- A Validation Study

View source ↗

Summary

A validation study evaluating the predictive accuracy of SAPI- for significant hepatic fibrosis in chronic hepatitis C patients with PNALT.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatic Fibrosis
• Hepatitis C

Snippet

Sponsor: National Taiwan University Hospital | Conditions: Chronic Hepatitis C, Hepatic Fibrosis | Status: COMPLETED